These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19912366)

  • 21. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
    Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
    Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
    Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The receptor expression pattern in ductal carcinoma in situ predicts recurrence.
    Kepple J; Henry-Tillman RS; Klimberg VS; Layeeque R; Siegel E; Westbrook K; Korourian S
    Am J Surg; 2006 Jul; 192(1):68-71. PubMed ID: 16769278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
    Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
    J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas.
    Tuck AB; O'Malley FP; Singhal H; Tonkin KS; Harris JF; Bautista D; Chambers AF
    Arch Pathol Lab Med; 1997 Jun; 121(6):578-84. PubMed ID: 9199622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
    Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
    Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Na+/H+ exchanger regulatory factor 1 expression levels in blood and tissue predict breast tumour clinical behaviour.
    Bellizzi A; Mangia A; Malfettone A; Cardone RA; Simone G; Reshkin SJ; Paradiso A
    Histopathology; 2011 Jun; 58(7):1086-95. PubMed ID: 21707710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
    Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
    Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
    Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
    Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
    Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
    Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of biomarkers in breast and prostate cancer.
    Grizzle WE; Myers RB; Arnold MM; Srivastava S
    J Cell Biochem Suppl; 1994; 19():259-66. PubMed ID: 7823598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal breast cancer: evaluation of histology and biological marker expression.
    Dublin EA; Millis RR; Smith P; Bobrow LG
    Br J Cancer; 1999 Jul; 80(10):1608-16. PubMed ID: 10408407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.